GWM
NBIX icon

Geneos Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Geneos Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-210
Closed -$26.4K – 2935
2025
Q2 		$26.4K Sell
210
-341
-62% -$39.1K ﹤0.01% 1898
2025
Q1 		$60.9K Buy
551
+457
+486% +$57.9K ﹤0.01% 1815
2024
Q4 		$12.8K Hold
94
– – ﹤0.01% 1942
2024
Q3 		$10.8K Buy
+94
New +$12.9K ﹤0.01% 1813
2024
Q2 		– Sell
-7
Closed -$965 – 2143
2024
Q1 		$965 Buy
+7
New +$956 ﹤0.01% 2027
2021
Q2 		– Sell
-11
Closed -$1K – 3022
2021
Q1 		$1K Buy
+11
New +$1.15K ﹤0.01% 3041
2020
Q4 		– Sell
-50
Closed -$4K – 2962
2020
Q3 		$4K Sell
50
-250
-83% -$28.9K ﹤0.01% 2266
2020
Q2 		$39K Sell
300
-190
-39% -$21K ﹤0.01% 1327
2020
Q1 		$43K Hold
490
– – ﹤0.01% 1185
2019
Q4 		$53K Buy
+490
New +$51.3K ﹤0.01% 1220

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geneos Wealth Management's NBIX Position: Q3 2025 in Review

Geneos Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 210 shares — an estimated $26.4K sold.

Geneos Wealth Management first reported a position in NBIX in Q4 2019 and held it in 10 quarters. The position peaked at $60.9K in Q1 2025. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Geneos Wealth Management reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 210 Neurocrine Biosciences shares in Q3 2025, an estimated $26.4K.
  • Geneos Wealth Management first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 10 quarters.
  • Geneos Wealth Management's Neurocrine Biosciences position peaked at $60.9K in Q1 2025.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.